n.a. (CRTX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 26.92M
Div & Yield N.A. (N.A)

Latest News

Law Firm Brower Piven Announces Class Action Lawsuit In Connection With Claims Of Breaches Of Fiduciary Duty By The Board Of Cornerstone Therapeutics, Inc. In Connection With A Proposed Buyout

Law Firm Brower Piven Announces Class Action Lawsuit In Connection With Claims Of Breaches Of Fiduciary Duty By The Board Of Cornerstone Therapeutics, Inc. In Connection With A Proposed Buyout

The securities litigation firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Delaware Chancery Court on behalf of all common stockholders ...

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Cornerstone Therapeutics, Inc.

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Cornerstone Therapeutics, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cornerstone Therapeutics, Inc.

Shareholder Rights Law Firm Johnson & Weaver, LLP, Is Investigating The Cornerstone Buyout

Shareholder Rights Law Firm Johnson & Weaver, LLP, Is Investigating The Cornerstone Buyout

Shareholder rights law firm Johnson & Weaver, LLP is investigating potential breaches of fiduciary duty in connection with the proposed buyout of North Carolina-based Cornerstone Therapeutics Inc.

Cornerstone Therapeutics Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Acquisition By Chiesi Farmaceutici

Cornerstone Therapeutics Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Acquisition By Chiesi Farmaceutici

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating the acquisition of Cornerstone Therapeutics, Inc.

Law Firm Brower Piven Announces Investigation Of Cornerstone Therapeutics, Inc. Proposed Acquisition

Law Firm Brower Piven Announces Investigation Of Cornerstone Therapeutics, Inc. Proposed Acquisition

The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Cornerstone Therapeutics, Inc.

Finkelstein Thompson LLP Announces Investigation Of Cornerstone Therapeutics Inc. Buyout

Finkelstein Thompson LLP Announces Investigation Of Cornerstone Therapeutics Inc. Buyout

The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Cornerstone Therapeutics Inc.

5 Biotech Stocks Under $10 Making Big Moves

5 Biotech Stocks Under $10 Making Big Moves

Keep these biotech stocks on your radar.

4 Health Care Stocks Under $10 Close to Breakouts

4 Health Care Stocks Under $10 Close to Breakouts

Keep these health care stocks on your radar.

Commit To Buy Cornerstone Therapeutics At $7.50, Earn 18.7% Annualized

Commit To Buy Cornerstone Therapeutics At $7.50, Earn 18.7% Annualized

Investors eyeing a purchase of Cornerstone Therapeutics Inc stock, but tentative about paying the going market price of $8.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $7.50 strike, which has a bid at the time of this writing of 50 cents.

Cornerstone Therapeutics Inc. Stock Upgraded (CRTX)

Cornerstone Therapeutics Inc. Stock Upgraded (CRTX)

Cornerstone Therapeutics (Nasdaq:CRTX) has been upgraded by TheStreet Ratings from a sell to hold.

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Cornerstone Therapeutics Inc. Shareholders

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Cornerstone Therapeutics Inc. Shareholders

Kirby McInerney LLP is investigating potential claims against the Board of Directors of Cornerstone Therapeutics Inc.

Cornerstone Therapeutics Shareholder Alert: Briscoe Law Firm And Powers Taylor, LLP Investigate Going Private Proposal

Cornerstone Therapeutics Shareholder Alert: Briscoe Law Firm And Powers Taylor, LLP Investigate Going Private Proposal

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating potential legal claims against the Board of Directors of...

31 Drugs Facing FDA Approval in 2012-2013

31 Drugs Facing FDA Approval in 2012-2013

An updated calendar listing FDA drug approval decisions and advisory panels for the remainder of 2012 and early 2013